ACRV Stock Analysis: Buy, Sell, or Hold?
ACRV - Acrivon Therapeutics, Inc. Common Stock
$2.21
0.01 (0.45%)
▲
5d:
+13.33%
30d:
+32.34%
90d:
+23.46%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ACRV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ACRV is 15.1% above its trading range ($1.92). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ACRV is 15.1% above its trading range ($1.92). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ACRV is currently trading at $2.21, which is considered extended relative to its 30-day fair value range of $1.56 to $1.92.
Technical Outlook: Technically, ACRV is showing sideways momentum. Immediate support is located at $1.69, while resistance sits at $2.39.
Market Sentiment: ACRV scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.50 (+420.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACRV is showing sideways momentum. Immediate support is located at $1.69, while resistance sits at $2.39.
Market Sentiment: ACRV scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.50 (+420.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.56 -
$1.92
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+15.1% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 420.4% below Wall St target ($11.50)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.56 -
$1.92
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.69
Resistance Level
$2.39
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.28
Wall Street Target
$11.50
(+420.4%)
Share & Embed Analysis
Last updated: August 22, 2026 11:04 PM ET
Data refreshes hourly during market hours. Next update: 12:04 AM
Data refreshes hourly during market hours. Next update: 12:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACRV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
